Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mosgorlombard wants to participate in precious metals trading on the Moscow Exchange

3/12/24 MGKL

Lukoil reports for 2023 by IFRS

3/12/24 LKOH

Fire at LUKOIL-Nizhegorodnefteorgsintez extinguished

3/12/24 LKOH

Ozon will become a resident of the Enem industrial zone in Adygea

3/12/24 OZON

Magadanenergo reported for 2023 by RAS

3/12/24 MAGE

Renaissance Insurance bought back 8% of shares from the market

3/12/24 RENI

M.Video will present an updated strategy at the end of the year

3/12/24 MVID

QIWI will not conduct a share buyback

3/12/24 QIWI

Abrau-Durso launched Russia's first production of Danza del Fuego rum

3/12/24 ABRD

Element Group will produce radio modules for base stations

3/12/24 AFKS